For the first time, Health Canada has approved a new drug that can slow the progression of Alzheimer’s disease and it’s giving new hope that the disease can be tackled early.

On Monday, Health Canada announced approval for lecanemab , commercially known as “Leqembi.”

The treatment has already been approved in some other countries, including the U.S., the U.K., Japan, Mexico and China. It is currently under regulatory review in 15 other countries and regions, including the European Union.

Lecanemab is meant for adults who have a clinical diagnosis of mild dementia due to Alzheimer’s disease.

Why is it a ‘big deal?’

Lecanemab is the first new Alzheimer’s treatment approved by Health Canada in more than a decade and the first to target the underlying biology of the disease, the Alz

See Full Page